← All trials
NCT06821685
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 13, 2025
- Primary completion
- Jul 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Feb 12, 2025
- Last posted
- Nov 17, 2025
- Enrollment
- 14
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing UniversityLead sponsor
- University of Science and Technology of ChinaCollaborator
- Nanjing UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.